menu
    • menu
    [{"orgOrder":0,"company":"Apogenix","sponsor":"Apogenix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apogenix \/ Apogenix","highestDevelopmentStatusID":"9","companyTruncated":"Apogenix \/ Apogenix"},{"orgOrder":0,"company":"Apogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"APG101","moa":"Tumor necrosis factor ligand superfamily member 6","graph1":"Oncology","graph2":"Phase II","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apogenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apogenix \/ Undisclosed"},{"orgOrder":0,"company":"Apogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"APG101","moa":"Tumor necrosis factor ligand superfamily member 6","graph1":"Oncology","graph2":"Phase I","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apogenix \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Apogenix \/ Undisclosed"},{"orgOrder":0,"company":"Apogenix","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Asunercept","moa":"||Tumor necrosis factor ligand superfamily member 6","graph1":"Oncology","graph2":"Phase II","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apogenix \/ Apogenix","highestDevelopmentStatusID":"8","companyTruncated":"Apogenix \/ Apogenix"},{"orgOrder":0,"company":"Apogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Asunercept","moa":"Tumor necrosis factor ligand superfamily member 6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apogenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apogenix \/ Undisclosed"},{"orgOrder":0,"company":"Apogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Asunercept","moa":"Tumor necrosis factor ligand superfamily member 6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apogenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apogenix \/ Undisclosed"},{"orgOrder":0,"company":"Apogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Asunercept","moa":"Tumor necrosis factor ligand superfamily member 6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apogenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apogenix \/ Undisclosed"},{"orgOrder":0,"company":"Apogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Asunercept","moa":"Tumor necrosis factor ligand superfamily member 6","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Apogenix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apogenix \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apogenix \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Apogenix

    Menu

    Apogenix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Asunercept

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease

                            Details : Asunercept is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            December 06, 2022

                            Lead Product(s) : Asunercept

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Asunercept,Temozolomide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : CANbridge Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First Patient Dosed in CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme...

                            Details : The results demonstrate that CAN008 has excellent safety and tolerability in patients with GBM and could potentially improve the quality life and the survival time of the patients.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 26, 2021

                            Lead Product(s) : Asunercept,Temozolomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : CANbridge Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxychloroquine Sulphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Recipient : University of Cologne

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            COVID-19: Targeted Treatment Trial Launched in Vienna

                            Details : ACOVACT is a randomised, controlled, multi-centre, open-label clinical trial sponsored by MedUni Vienna. Within ACOVACT, different treatments for COVID-19 are compared to one another. The trial will evaluate Fas ligand blocker asunercept.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 22, 2020

                            Lead Product(s) : Hydroxychloroquine Sulphate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Recipient : University of Cologne

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Asunercept

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apogenix Advances Clinical Development of CD95L Inhibitor Asunercept in European COVID-19 Phase II Trial

                            Details : The ASUNCTIS trial is a multi-center, randomized, controlled, open-label phase II trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 13, 2020

                            Lead Product(s) : Asunercept

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Asunercept

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Asunercept in Patients With Severe COVID-19

                            Details : Asunercept is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 02, 2020

                            Lead Product(s) : Asunercept

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Asunercept

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apogenix to Start European Clinical Phase II Trial with Asunercept in COVID-19 Patients

                            Details : The ASUNCTIS trial will be a multi-center, randomized, controlled, open-label trial to assess the efficacy and safety of asunercept in patients with severe COVID-19 disease.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 28, 2020

                            Lead Product(s) : Asunercept

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            APG101 in Myelodysplastic Syndrome

                            Details : APG101 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Myelodysplastic Syndromes.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 29, 2012

                            Lead Product(s) : APG101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed

                            Apogenix

                            Germany arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APG101

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            APG101 in Glioblastoma

                            Details : APG101 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 19, 2010

                            Lead Product(s) : APG101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth